Back to Search Start Over

Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA)

Authors :
Kawashiri, Shin-Ya
Endo, Yushiro
Nishino, Ayako
Okamoto, Momoko
Tsuji, Sosuke
Takatani, Ayuko
Shimizu, Toshimasa
Sumiyoshi, Remi
Koga, Tomohiro
Iwamoto, Naoki
Ichinose, Kunihiro
Tamai, Mami
Nakamura, Hideki
Origuchi, Tomoki
Aramaki, Toshiyuki
Ueki, Yukitaka
Yoshitama, Tamami
Eiraku, Nobutaka
Matsuoka, Naoki
Okada, Akitomo
Fujikawa, Keita
Hamada, Hiroaki
Nagano, Shuji
Tada, Yoshifumi
Kawakami, Atsushi
Source :
Medicine
Publication Year :
2021
Publisher :
Lippincott Williams & Wilkins, 2021.

Abstract

We evaluated the effect of abatacept treatment on osteoclast-related biomarkers and explored whether the biomarkers are associated with the therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. We enrolled 44 RA patients treated with abatacept from a multicenter prospective ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug therapy. We evaluated the disease activity score (DAS) 28-CRP (C-reactive protein), musculoskeletal ultrasound scores including the total grayscale score (GS)/power Doppler (PD) score and the serum concentrations of isoform 5b of tartrate-resistant acid phosphate (TRACP-5b) and soluble receptor activator of nuclear factor-κB ligand (sRANKL) at baseline and at 3 and 6 months of treatment. “PD responder” was defined as a patient whose Δtotal PD score over 6 months was greater than the median change of that. Abatacept significantly improved DAS28-CRP as well as the total GS/PD score over 6 months. Serum TRACP-5b was significantly elevated and serum sRANKL was significantly decreased at 6 months (P

Details

Language :
English
ISSN :
15365964 and 00257974
Volume :
100
Issue :
28
Database :
OpenAIRE
Journal :
Medicine
Accession number :
edsair.pmid..........865de49d14a9dde91621a6a5e4ede161